The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1393
Bisphosphonates - Duration of Use Revisited
The full article is available to subscribers Subscriber Login   
Revised 7/6/12: In the first sentence of the conclusion, the words "with osteoporosis" were removed immediately after "women".

Long-term use of bisphosphonates for prevention and treatment of osteoporosis has been associated with osteonecrosis of the jaw, atypical fractures of the femur, and possibly esophageal cancer.1,2 So for how long should patients take them?

CLINICAL STUDIES — The limited evidence comes mainly from 3 studies in postmenopausal women with low bone mineral density.3

The FLEX trial randomized 1099 women who had taken alendronate (Fosamax, and others) for 5 years to continued alendronate or placebo for 5 additional years. Continuation of treatment with alendronate decreased the incidence of clinical vertebral fractures (2.4% vs. 5.3%). It did not decrease the incidence of nonvertebral fractures. A post hoc subgroup analysis found that an additional 5 years of alendronate did reduce the incidence of nonvertebral fractures in patients ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Bisphosphonates - Duration of Use Revisited
Article code: 1393a
 Electronic, downloadable article - $25